Literature DB >> 11601139

Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course.

A Mansoor1, L J Medeiros, D M Weber, R Alexanian, K Hayes, D Jones, R Lai, A Glassman, C E Bueso-Ramos.   

Abstract

We correlated bone marrow cytogenetic findings with morphologic and immunophenotypic data in 37 patients with lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM). Each LPL/WM case was classified as lymphoplasmacytoid (n = 18), lymphoplasmacytic (n = 10), or polymorphous (n = 9) using the Kiel criteria. Of 12 cases with chromosomal abnormalities, a single numeric abnormality was present in 4 and a complex karyotype in 8. The most common numeric abnormalities were and -8 in 3 cases each; the most common structural abnormality was del(6q) in 6 cases. Cytogenetic abnormalities were significantly less common in the lymphoplasmacytic and lymphoplasmacytoid groups (5/28 [18%]) compared with the polymorphous group (7/9 [78%]). Clinical follow-up was available for 28 patients for a median of 36 months. Six (67%) of 9 patients with aneuploid tumors, including 4 with polymorphous subtype, subsequently had clinical progression or developed high-grade lymphoma. In contrast, 4 (21%) of 19 patients with diploid tumors, including 1 of polymorphous type, developed clinical progression or high-grade lymphoma. We conclude that abnormal cytogenetic findings in LPL/WM correlate with the polymorphous subtype and poor prognosis.

Entities:  

Mesh:

Year:  2001        PMID: 11601139     DOI: 10.1309/6U88-357U-UKJ5-YPT3

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families.

Authors:  Mary L McMaster; Lynn R Goldin; Yan Bai; Monica Ter-Minassian; Stefan Boehringer; Therese R Giambarresi; Linda G Vasquez; Margaret A Tucker
Journal:  Am J Hum Genet       Date:  2006-08-31       Impact factor: 11.025

3.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.

Authors:  Wee J Chng; Roelandt F Schop; Tammy Price-Troska; Irene Ghobrial; Neil Kay; Diane F Jelinek; Morie A Gertz; Angela Dispenzieri; Martha Lacy; Robert A Kyle; Philip R Greipp; Renee C Tschumper; Rafael Fonseca; Peter Leif Bergsagel
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

4.  Low-grade B-Cell lymphomas with plasmacytic differentiation lack PAX5 gene rearrangements.

Authors:  Tracy I George; Joanna E Wrede; Charles D Bangs; Athena M Cherry; Roger A Warnke; Daniel A Arber
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

Review 5.  Genetic factors and pathogenesis of Waldenström's macroglobulinemia.

Authors:  Jorge Monge; Esteban Braggio; Stephen M Ansell
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 6.  Novel treatment options for Waldenström macroglobulinemia.

Authors:  Houry Leblebjian; Amit Agarwal; Irene Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09

Review 7.  The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.

Authors:  Steven H Swerdlow; Isinsu Kuzu; Ahmet Dogan; Stephan Dirnhofer; John K C Chan; Birgitta Sander; German Ott; Luc Xerri; Leticia Quintanilla-Martinez; Elias Campo
Journal:  Virchows Arch       Date:  2015-10-10       Impact factor: 4.064

8.  Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.

Authors:  Jun Wang; Yuting Yan; Wenjie Xiong; Ge Song; Yi Wang; Jiawei Zhao; Yujiao Jia; Chengwen Li; Zhen Yu; Ying Yu; Jiawen Chen; Yang Jiao; Tingyu Wang; Rui Lyu; Qinghua Li; Yueshen Ma; Wei Liu; Dehui Zou; Gang An; Qi Sun; Huijun Wang; Zhijian Xiao; Jianxiang Wang; Lugui Qiu; Shuhua Yi
Journal:  Blood Adv       Date:  2022-07-12

9.  Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.

Authors:  Xin Cao; Qing Ye; Robert Z Orlowski; Xiaoxiao Wang; Sanam Loghavi; Meifeng Tu; Sheeba K Thomas; Jatin Shan; Shaoying Li; Muzaffar Qazilbash; C Cameron Yin; Donna Weber; Roberto N Miranda; Zijun Y Xu-Monette; L Jeffrey Medeiros; Ken H Young
Journal:  J Hematol Oncol       Date:  2015-06-24       Impact factor: 17.388

10.  Lymphoplasmacytic non-Hodgkin lymphoma/Waldenström's macroglobulinemia with CD5+, CD23+, and CD10-.

Authors:  Guido D'Angelo; Anna Maria Hotz; Marta Monti
Journal:  Blood Res       Date:  2013-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.